Person:
TANGİLNTİZ, AİSE

Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
AİSE
Last Name
TANGİLNTİZ
Name
Email Address
Birth Date

Filters

2018 - 201912020 - 20212
Reset filters

Settings

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    State and trait anxiety among medical staff during the first month of COVID-19 pandemic: A sample from Turkey
    (2021-08-01T00:00:00Z) ŞAHAN, EBRU; TANGİLNTİZ, AİSE; ŞAHAN, EBRU; TANGİLNTİZ, AİSE
    Objectives During the COVID-19 pandemic, excessive workload, a rapidly changing workplace environment, the danger of carrying the virus and transmitting the disease to their families, relatives and those they live with creates stress for the medical workers. In our study, we aimed to evaluate the state and trait anxiety levels of healthcare professionals who encounter patients with suspected COVID-19 infection and related factors. Method Data were collected from healthcare professionals working with patients diagnosed or suspected with COVID-19 via online self-report questionnaire between 9-19 April 2020. The state (STAI-S) and trait anxiety (STAI-T) scale was used to measure anxiety. Results A total of 291 healthcare professionals, 216 women and 75 men, participated in the study. Women-s state and trait anxiety were significantly higher than men-s. 11 participants without any lifetime psychiatric illness experienced psychiatric symptoms and consulted to a psychiatrist. The state anxiety of those who have children, nurses and those working in branches directly related to the pandemic (Infectious Diseases, Respiratory Diseases, Emergency Medicine, Internal Medicine, Radiology, Anesthesiology and Reanimation) was higher than others. The state anxiety of those who thought they were not protected with personal protective equipment and those who did not stay in their own home was higher than others. Conclusions At the forefront of the fight against COVID-19, there are medical personnel who pay a serious psychological cost. Especially in terms of anxiety, we should pay attention to women, workers with children, nurses and people working in branches that are directly related to pandemics.
  • No Thumbnail Available
    PublicationMetadata only
    Bilateral Serous Macular Detachment After Attempted Suicide with Pregabalin
    (2018-10-01T00:00:00Z) Tanyildiz, Burak; Kandemir, Baran; Mangan, Mehmet Serhat; TANGİLNTİZ, AİSE; Goktas, Eren; Simsek, Saban; TANGİLNTİZ, AİSE
    A 24-year-old female presented with bilateral vision loss following attempted suicide with pregabalin. Her best-corrected visual acuity (BCVA) was 20/40 in the right eye and 20/50 in the left eye. The bilateral visual disturbance was associated with serous macular detachment. Fundus examination of both eyes showed foveal serous retinal detachment, which was confirmed by optical coherence tomography. Topical nepafenac 0.1% eye drops were started as single drop every 8 hours for 4 weeks. One month later, the serous macular detachment had regressed and BCVA increased to 20/20 in both eyes. To the best of our knowledge, this is the first reported case of bilateral serous macular detachment presumably caused by pregabalin intoxication.
  • Thumbnail Image
    PublicationOpen Access
    The first male case with fluoxetine induced hair loss and review of the literature
    (2021-01-01T00:00:00Z) Karacan, FATMA; Tangilntiz, A.; KIRPINAR, İSMET; AKYÜZ KARACAN, FATMA; TANGİLNTİZ, AİSE; KIRPINAR, İSMET
    Objective: Fluoxetine is the drug of choice in the treatment of depression. It is widely preferred due to fewer side effects and greater tolerability. Hair loss is a frequent adverse effect that may occur by psychotropic drug use and that can remit by its cessation. Patients and methods: We present the diagnosis and treatment of a 26-year-old male patient. He was diagnosed with depression without psychotic features according to the DSM-V criteria and was administered fluoxetine in a dose of 20 mg/day. Results: Six weeks after the initiation of the fluoxetine treatment, the patient reported hair loss in the frontal area of the skull. These complaints regressed after cessation of drug. Conclusions: Hair loss appears to be a rare side effect of fluoxetine-based treatment. Dermatologists and psychiatrists must be informed about this adverse side effect. There might be differences in the risk of hair loss between the various SSRIs and the risk might be higher in female than in male. This male patient was the first case as far as we know in the literature. It should be kept in mind that hair loss may be observed in patients treated with fluoxetine and should be questioned in both male and female.